ZA201603167B - Ccr6 compounds - Google Patents
Ccr6 compoundsInfo
- Publication number
- ZA201603167B ZA201603167B ZA2016/03167A ZA201603167A ZA201603167B ZA 201603167 B ZA201603167 B ZA 201603167B ZA 2016/03167 A ZA2016/03167 A ZA 2016/03167A ZA 201603167 A ZA201603167 A ZA 201603167A ZA 201603167 B ZA201603167 B ZA 201603167B
- Authority
- ZA
- South Africa
- Prior art keywords
- ccr6
- compounds
- ccr6 compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
- A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
- A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pulmonology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Reproductive Health (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361910838P | 2013-12-02 | 2013-12-02 | |
| PCT/US2014/068152 WO2015084842A1 (en) | 2013-12-02 | 2014-12-02 | Ccr6 compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA201603167B true ZA201603167B (en) | 2019-09-25 |
Family
ID=53274030
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2016/03167A ZA201603167B (en) | 2013-12-02 | 2016-05-11 | Ccr6 compounds |
Country Status (13)
| Country | Link |
|---|---|
| US (4) | US9340509B2 (https=) |
| EP (1) | EP3076968B1 (https=) |
| JP (1) | JP6563947B2 (https=) |
| KR (1) | KR102331833B1 (https=) |
| CN (1) | CN105960237B (https=) |
| AU (1) | AU2014360743C1 (https=) |
| CA (1) | CA2930148C (https=) |
| EA (1) | EA029826B1 (https=) |
| ES (1) | ES2735360T3 (https=) |
| IL (1) | IL245704B (https=) |
| MX (1) | MX2016007128A (https=) |
| WO (1) | WO2015084842A1 (https=) |
| ZA (1) | ZA201603167B (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
| KR20200037857A (ko) | 2017-08-14 | 2020-04-09 | 알러간, 인코포레이티드 | 3,4-이치환된 3-시클로부텐-1,2-디온 및 그의 용도 |
| BR112020018094A2 (pt) | 2018-03-08 | 2020-12-22 | Incyte Corporation | Compostos de aminopirazina diol como inibidores de pi3k-¿ |
| US11046658B2 (en) | 2018-07-02 | 2021-06-29 | Incyte Corporation | Aminopyrazine derivatives as PI3K-γ inhibitors |
| KR102880470B1 (ko) | 2018-10-23 | 2025-11-03 | 다이이찌 산쿄 가부시키가이샤 | 바이아릴 유도체 |
| CN117018202A (zh) * | 2019-07-08 | 2023-11-10 | 上海交通大学医学院附属瑞金医院 | 趋化因子受体ccr6抑制剂在预防银屑病复发中的新应用 |
| BR112021025888A2 (pt) | 2019-07-10 | 2022-04-26 | Chemocentryx Inc | Indanos como inibidores de pd-l1 |
| JP7736678B2 (ja) | 2019-10-16 | 2025-09-09 | ケモセントリックス,インコーポレイティド | Pd-l1疾患の処置のためのヘテロアリール-ビフェニルアミド |
| ES3064674T3 (en) | 2019-10-16 | 2026-04-28 | Chemocentryx Inc | Heteroaryl-biphenyl amines for the treatment of pd-l1 diseases |
| AU2021266148A1 (en) | 2020-04-30 | 2023-01-05 | Idorsia Pharmaceuticals Ltd | Azetidin-3-ylmethanol derivatives as CCR6 receptor modulators |
| AU2022328634A1 (en) | 2021-08-18 | 2024-02-22 | Chemocentryx, Inc. | Aryl sulfonyl compounds as ccr6 inhibitors |
| WO2023023532A2 (en) | 2021-08-18 | 2023-02-23 | Chemocentryx, Inc. | Aryl sulfonyl (hydroxy) piperidines as ccr6 inhibitors |
| WO2023057548A1 (en) | 2021-10-07 | 2023-04-13 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| WO2023072924A1 (en) | 2021-10-26 | 2023-05-04 | Idorsia Pharmaceuticals Ltd | Ccr6 receptor modulators |
| TW202325271A (zh) | 2021-10-28 | 2023-07-01 | 瑞士商愛杜西亞製藥有限公司 | Ccr6受體調節劑 |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3944553A (en) | 1974-02-13 | 1976-03-16 | Trw Inc. | Bis quinoline peri acids |
| US4021409A (en) | 1975-06-19 | 1977-05-03 | The United States Of America As Represented By The Secretary Of The Air Force | Thermally stable benzimidazonaphthyridine compositions |
| US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
| US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
| US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
| LU86084A1 (fr) | 1985-09-20 | 1987-04-02 | Faco Sa | Apparei de massage electrique |
| US5102417A (en) | 1985-11-07 | 1992-04-07 | Expandable Grafts Partnership | Expandable intraluminal graft, and method and apparatus for implanting an expandable intraluminal graft |
| US4800882A (en) | 1987-03-13 | 1989-01-31 | Cook Incorporated | Endovascular stent and delivery system |
| US4886062A (en) | 1987-10-19 | 1989-12-12 | Medtronic, Inc. | Intravascular radially expandable stent and method of implant |
| WO1990013332A1 (en) | 1989-05-11 | 1990-11-15 | Cedars-Sinai Medical Center | Stent with sustained drug delivery |
| DE69110787T2 (de) | 1990-02-28 | 1996-04-04 | Medtronic, Inc., Minneapolis, Minn. | Intraluminale prothese mit wirkstoffeluierung. |
| US5429634A (en) | 1993-09-09 | 1995-07-04 | Pdt Systems | Biogenic implant for drug delivery and method |
| US5419760A (en) | 1993-01-08 | 1995-05-30 | Pdt Systems, Inc. | Medicament dispensing stent for prevention of restenosis of a blood vessel |
| US6774278B1 (en) | 1995-06-07 | 2004-08-10 | Cook Incorporated | Coated implantable medical device |
| US5833651A (en) | 1996-11-08 | 1998-11-10 | Medtronic, Inc. | Therapeutic intraluminal stents |
| US6294192B1 (en) | 1999-02-26 | 2001-09-25 | Lipocine, Inc. | Triglyceride-free compositions and methods for improved delivery of hydrophobic therapeutic agents |
| US6770729B2 (en) | 2002-09-30 | 2004-08-03 | Medtronic Minimed, Inc. | Polymer compositions containing bioactive agents and methods for their use |
| AU2005245401A1 (en) * | 2004-05-12 | 2005-12-01 | Chemocentryx | Aryl sulfonamides |
| DK1838674T3 (da) * | 2005-01-14 | 2011-06-14 | Chemocentryx Inc | Heteroarylsulfonamider og CCR2 |
| WO2008010934A2 (en) * | 2006-07-14 | 2008-01-24 | Chemocentryx, Inc. | Triazolyl phenyl benzenesulfonamides |
| CN101511800B (zh) | 2006-07-14 | 2013-02-27 | 坎莫森特里克斯公司 | 三唑基苯基苯磺酰胺 |
| WO2009008552A1 (en) | 2007-07-11 | 2009-01-15 | Taisho Pharmaceutical Co., Ltd. | 8-aryl-4-alkylpyrrolo[2,3,4-de]quinolin-5(4h)-one and 8-aryl-4-alkyl-4,5-dihydropyrrolo[2,3,4-de]quinolin-5-ol derivatives |
| JP5306344B2 (ja) * | 2007-07-12 | 2013-10-02 | ケモセントリックス, インコーポレイテッド | 炎症の治療のためのccr2モジュレーターとしての縮合ヘテロアリールピリジルおよびフェニルベンゼンスルホンアミド |
| AR070513A1 (es) * | 2007-08-01 | 2010-04-14 | Lundbeck & Co As H | Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor |
| ES2554513T3 (es) | 2008-05-23 | 2015-12-21 | Novartis Ag | Derivados de quinolinas y quinoxalinas como inhibidores de la proteína tirosina quinasa |
| CA2725014C (en) * | 2008-05-30 | 2014-06-17 | Amgen Inc. | Inhibitors of pi3 kinase |
| US8546405B2 (en) | 2008-12-23 | 2013-10-01 | Abbott Laboratories | Anti-viral compounds |
| JP2013504325A (ja) | 2009-09-09 | 2013-02-07 | アビラ セラピューティクス, インコーポレイテッド | Pi3キナーゼインヒビターおよびその使用 |
| TWI487486B (zh) | 2009-12-01 | 2015-06-11 | Syngenta Participations Ag | 以異唑啉衍生物為主之殺蟲化合物 |
| US9284301B2 (en) * | 2010-03-25 | 2016-03-15 | Merck Sharp & Dohme Corp. | Soluble guanylate cyclase activators |
| CN103347520A (zh) | 2010-10-13 | 2013-10-09 | 波士顿大学管理委员会 | 用作癌症化学治疗的晚期sv40因子(lsf)的抑制剂 |
| KR101985184B1 (ko) | 2011-01-28 | 2019-06-03 | 주식회사 동진쎄미켐 | 신규한 유기염료 및 이의 제조방법 |
| TW201311149A (zh) | 2011-06-24 | 2013-03-16 | Ishihara Sangyo Kaisha | 有害生物防治劑 |
| US9307766B2 (en) | 2011-08-25 | 2016-04-12 | Syngenta Participations Ag | Isoxazoline derivatives as insecticidal compounds |
| FR2981935B1 (fr) * | 2011-10-28 | 2015-08-07 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| FR2981934B1 (fr) | 2011-10-28 | 2013-12-20 | Galderma Res & Dev | Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines. |
| RU2627268C2 (ru) * | 2012-02-29 | 2017-08-04 | Хемоцентрикс, Инк. | Аза-арил-1Н-пиразол-1-ил-сульфонамиды |
| EP3076968B1 (en) | 2013-12-02 | 2019-04-17 | ChemoCentryx, Inc. | Ccr6 compounds |
-
2014
- 2014-12-02 EP EP14867718.0A patent/EP3076968B1/en active Active
- 2014-12-02 CN CN201480065637.7A patent/CN105960237B/zh active Active
- 2014-12-02 KR KR1020167017459A patent/KR102331833B1/ko active Active
- 2014-12-02 ES ES14867718T patent/ES2735360T3/es active Active
- 2014-12-02 AU AU2014360743A patent/AU2014360743C1/en active Active
- 2014-12-02 EA EA201691141A patent/EA029826B1/ru not_active IP Right Cessation
- 2014-12-02 US US14/557,949 patent/US9340509B2/en active Active
- 2014-12-02 CA CA2930148A patent/CA2930148C/en active Active
- 2014-12-02 JP JP2016556693A patent/JP6563947B2/ja active Active
- 2014-12-02 MX MX2016007128A patent/MX2016007128A/es active IP Right Grant
- 2014-12-02 WO PCT/US2014/068152 patent/WO2015084842A1/en not_active Ceased
-
2016
- 2016-03-18 US US15/074,965 patent/US9795599B2/en active Active
- 2016-05-11 ZA ZA2016/03167A patent/ZA201603167B/en unknown
- 2016-05-18 IL IL24570416A patent/IL245704B/en active IP Right Grant
-
2017
- 2017-09-19 US US15/709,012 patent/US10117865B2/en active Active
-
2018
- 2018-10-03 US US16/150,796 patent/US10786494B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US10786494B2 (en) | 2020-09-29 |
| IL245704B (en) | 2019-10-31 |
| EP3076968A1 (en) | 2016-10-12 |
| EA029826B1 (ru) | 2018-05-31 |
| US10117865B2 (en) | 2018-11-06 |
| US20190167659A1 (en) | 2019-06-06 |
| US20180092902A1 (en) | 2018-04-05 |
| KR102331833B1 (ko) | 2021-11-25 |
| AU2014360743B2 (en) | 2020-07-16 |
| MX2016007128A (es) | 2016-08-11 |
| AU2014360743C1 (en) | 2021-01-28 |
| US9795599B2 (en) | 2017-10-24 |
| AU2014360743A1 (en) | 2016-05-26 |
| CA2930148C (en) | 2023-04-11 |
| US20160296508A1 (en) | 2016-10-13 |
| EA201691141A1 (ru) | 2017-01-30 |
| US9340509B2 (en) | 2016-05-17 |
| CN105960237A (zh) | 2016-09-21 |
| CN105960237B (zh) | 2020-03-31 |
| JP2016540051A (ja) | 2016-12-22 |
| IL245704A0 (en) | 2016-07-31 |
| EP3076968A4 (en) | 2017-04-12 |
| EP3076968B1 (en) | 2019-04-17 |
| CA2930148A1 (en) | 2015-06-11 |
| JP6563947B2 (ja) | 2019-08-21 |
| WO2015084842A1 (en) | 2015-06-11 |
| ES2735360T3 (es) | 2019-12-18 |
| US20150175547A1 (en) | 2015-06-25 |
| KR20160096634A (ko) | 2016-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201600353B (en) | Cyanotriazole compounds | |
| IL240903A0 (en) | Tetrahydropyrrolothiazine compounds | |
| GB201309085D0 (en) | Compounds | |
| GB201310542D0 (en) | Compounds | |
| GB201302927D0 (en) | Compounds | |
| IL245704B (en) | ccr6 compounds | |
| GB201311951D0 (en) | Compounds | |
| GB201309508D0 (en) | Compounds | |
| GB201317619D0 (en) | Compounds | |
| GB201319363D0 (en) | Compounds | |
| GB201320636D0 (en) | Compounds | |
| GB201311953D0 (en) | Compounds | |
| AP3850A (en) | Azetidinyloxyphenylpyrrolidine compounds | |
| GB201312901D0 (en) | Compounds | |
| EP2948457A4 (en) | COMPOUNDS | |
| GB201306794D0 (en) | Compounds | |
| GB201318461D0 (en) | Compounds | |
| GB201316014D0 (en) | Compounds | |
| GB201310460D0 (en) | Compounds | |
| GB201321553D0 (en) | Compounds | |
| GB201321554D0 (en) | Compounds | |
| GB201321283D0 (en) | Compounds | |
| GB201318323D0 (en) | Compounds | |
| GB201318143D0 (en) | Compounds | |
| GB201317118D0 (en) | Compounds |